Zepbound Safety Guide

Zepbound side effects: what the data actually shows

By Iacob Pastina · Independent Researcher & Publisher · Updated May 2026

The most common Zepbound side effects are gastrointestinal: nausea (33%), diarrhea (25%), constipation (20%), and vomiting (12%). 98% of GI side effects in the SURMOUNT-1 trial were mild to moderate, peaked during the 24-week dose escalation, and improved over time. Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist, its dual mechanism produces higher weight loss than Wegovy (20.9% vs 14.9% at maintenance dose) but a longer 24-week titration. All percentages below come from the FDA-approved Zepbound prescribing information.

Choosing between Zepbound and Wegovy? See our Wegovy vs Zepbound 2026 head-to-head for cost, effectiveness, and side-effect comparison. Or read the Wegovy side effects deep dive if you're weighing both options.

Call your doctor or 911 immediately if you experience:

• Severe upper abdominal pain radiating to the back (possible pancreatitis, call 911)
• Difficulty breathing, throat swelling, or widespread hives (call 911)
• Inability to keep fluids down for 24+ hours (kidney-injury risk, call your provider or ER)
• Sharp upper-right pain after fatty meals with fever or jaundice (gallbladder, provider call)
• New or worsening suicidal thoughts (call your provider AND 988)

Report any serious adverse event to FDA MedWatch.

Common side effects: rates from the Zepbound label

Source: FDA-approved prescribing information for Zepbound (tirzepatide 2.5mg, 15mg), based on the SURMOUNT-1 trial published in NEJM (2022).

Side effect	Rate	Severity	When it peaks
Nausea	33%	Mild to moderate	Weeks 4-12 (during dose escalation)
Diarrhea	25%	Mild to moderate	Weeks 1-12
Constipation	20%	Mild	Weeks 4-20 (worsens as appetite drops)
Abdominal pain	18%	Mild cramping (severe pain is a red flag)	Weeks 1-8
Vomiting	12%	Mild to moderate	Weeks 4-12
Injection site reactions	8%	Mild, redness, itching, mild swelling	First 24 hours after injection
Headache	13%	Mild	Weeks 1-4
Fatigue	8%	Mild	Weeks 1-8
Dyspepsia (indigestion)	9%	Mild	Throughout treatment
Hair loss (telogen effluvium)	6%	Cosmetic, temporary	Months 3-6 (related to rapid weight loss, not the drug directly, note this is 2× Wegovy's rate)

What to expect, week by week

Zepbound uses a 24-week dose-escalation schedule from 2.5mg starter to the maintenance dose of 15mg, stepping every 4 weeks. The longer titration (vs Wegovy's 16 weeks) tends to reduce peak GI symptoms but extends the side-effect window.

Weeks 1-4 (2.5mg starter)

What's typical: Mild nausea (10-15% of patients), occasional appetite reduction starts. Most users tolerate the starter dose well, it's intentionally sub-therapeutic to let the gut adjust.

Red flags: Persistent vomiting, severe abdominal pain, allergic reaction symptoms.

Weeks 5-8 (5mg therapeutic minimum)

What's typical: First therapeutic dose. Nausea picks up (15-25% baseline). Appetite suppression more noticeable. SURMOUNT-1 showed measurable weight loss begins here.

Red flags: Inability to keep fluids down for 24+ hours, severe upper abdominal pain radiating to back, fever.

Weeks 9-12 (7.5mg)

What's typical: GI symptoms commonly peak. Constipation more common as caloric intake drops. By week 12 most users have lost 5-8% of baseline body weight.

Red flags: Worsening symptoms instead of improving, discuss dose-hold with your provider before escalating to 10mg.

Weeks 13-16 (10mg)

What's typical: Many users plateau briefly during this transition. GI symptoms typically stabilizing. Hair shedding (telogen effluvium) may begin around month 3-4 in some users.

Red flags: New or worsening upper-right abdominal pain (gallbladder), severe fatigue with low urine output (kidney).

Weeks 17-20 (12.5mg)

What's typical: Continued weight loss, GI side effects diminishing for most users. Some patients stop here if results are sufficient and tolerance is good, 12.5mg is a clinically valid maintenance dose.

Red flags: Severe hair shedding interfering with quality of life, review protein intake (60-80g/day target) and iron/biotin levels.

Weeks 21-24+ (15mg maintenance)

What's typical: Highest approved dose. SURMOUNT-1 showed 20.9% average weight loss at 72 weeks at this dose. GI symptoms minimal for most users by this point.

Red flags: Any new symptom that emerges months into treatment warrants a provider call, late-onset pancreatitis and gallbladder issues do occur, especially given Zepbound's higher weight loss rate.

Management protocols for the most common side effects

Nausea (33% of patients)

• Eat smaller, more frequent meals (5-6 small instead of 3 large)
• Avoid fatty, fried, spicy, or highly aromatic foods during dose escalation
• Stay hydrated with small sips throughout the day; ginger or peppermint tea helps many users
• Take Zepbound on the same day each week, many providers suggest a Friday or Saturday so peak effects fall on a low-stress weekend
• Most providers will hold dose escalation for 4 additional weeks if nausea is intolerable rather than push to the next dose. Zepbound's 6 dose levels give more flexibility than Wegovy's 5.

Constipation (20%), Zepbound's most under-discussed side effect

• Increase fiber gradually (25-30g/day), too much too fast worsens GI symptoms
• Drink at least 64oz of water daily, more if active
• Walking 30 minutes daily helps gut motility
• OTC stool softeners (docusate) are safe for short-term use; check with provider before laxatives
• Persistent constipation past 1 week with abdominal distension warrants a provider call
• Note: Zepbound's constipation rate (20%) is lower than Wegovy's (24%) but persists longer because the 24-week titration extends the window when caloric intake drops

Diarrhea (25%) and Vomiting (12%)

• Maintain hydration as the priority, water plus electrolytes (sports drinks, oral rehydration salts)
• BRAT diet (bananas, rice, applesauce, toast) for diarrhea
• Avoid caffeine, alcohol, and dairy during acute symptoms
• If you cannot keep fluids down for 24 hours, call your provider, risk of dehydration-induced kidney injury
• Zepbound vomiting rate (12%) is half of Wegovy's (24%), if you're struggling more than expected, a dose-hold is reasonable

Hair shedding (6%), 2× Wegovy's rate

• Zepbound produces more rapid weight loss (20.9% vs 14.9%), and faster loss = more telogen effluvium
• This is the body's response to rapid weight change, not the drug acting on hair follicles directly
• Ensure 60-80g/day of protein intake (this is harder than it sounds when appetite is suppressed)
• Test ferritin (iron storage), vitamin D, and biotin BEFORE supplementing, random supplementation can mask deficiencies
• Regrowth typically begins 3-6 months after weight stabilizes. Plan for the long tail.

Injection site reactions (8%)

• Rotate injection sites between abdomen, thigh, and upper arm, never inject in the same spot twice in a row
• Allow the pen to reach room temperature before injecting (15-30 min out of fridge)
• Mild redness or itching for 24 hours is normal; persistent welts or spreading rash warrant a provider call
• If a reaction recurs at every site, talk to your provider about technique review or potential hypersensitivity

Serious side effects, recognize these red flags

Rare but serious. Knowing the warning signs is the difference between a manageable problem and an emergency. Note: Zepbound's gallbladder risk is slightly elevated vs Wegovy because rapid weight loss is the primary driver of gallstones, and Zepbound produces more loss.

Pancreatitis

<0.5% (rare but serious)

Red-flag symptoms: Severe upper abdominal pain radiating to the back, with persistent nausea or vomiting

Action: STOP Zepbound and seek emergency care immediately. Do not restart without provider clearance.

Gallbladder problems

0.6% (gallstones), 0.2% (cholecystitis)

Red-flag symptoms: Sharp upper-right abdominal pain after fatty meals, fever, jaundice. Rapid weight loss is the primary risk factor, Zepbound's higher loss rate (20.9%) means this risk is real for some patients.

Action: Contact your provider for imaging. May require surgical removal in 0.3-0.6% of cases.

Kidney injury (acute)

Rare

Red-flag symptoms: Decreased urine output, swelling, fatigue, usually after persistent vomiting or diarrhea causing dehydration

Action: Maintain aggressive hydration during GI symptoms. If you cannot keep fluids down for 24 hours, contact your provider or ER.

Hypoglycemia

Variable, primarily in patients also taking insulin or sulfonylureas

Red-flag symptoms: Shakiness, sweating, confusion, rapid heartbeat, blurred vision

Action: Treat immediately with 15g fast-acting carbs (juice, glucose tablets). Recheck in 15 minutes. Discuss insulin/sulfonylurea dose reduction with your prescriber if recurring.

Severe allergic reaction (anaphylaxis)

Rare (<0.1%)

Red-flag symptoms: Difficulty breathing, throat or facial swelling, widespread hives, drop in blood pressure

Action: CALL 911. Do not drive yourself.

Suicidal ideation

Under FDA post-marketing review, no causal link established

Red-flag symptoms: New or worsening depression, mood changes, self-harm thoughts

Action: Contact your provider AND report to FDA MedWatch (1-800-FDA-1088). The 988 Suicide & Crisis Lifeline is available 24/7.

The boxed warning: thyroid C-cell tumors

Zepbound carries a boxed warning, the FDA's strongest warning level, for thyroid C-cell tumors. This is based on rodent studies; no causal link has been established in humans.

Zepbound is contraindicated in patients with:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Your prescriber should screen for these before initiating Zepbound. If a telehealth provider does not ask about thyroid history during intake, treat that as a quality flag, programs with stronger clinical oversight (board-certified obesity medicine physicians, comprehensive intake) catch this systematically.

Choosing a provider who handles Zepbound's 24-week titration well

Zepbound's longer 24-week ramp matters more than Wegovy's 16-week ramp when picking a provider. You'll be in the side-effect-prone phase for 6 months. Programs that include regular check-ins, willingness to hold dose escalation, and quarterly labs to catch issues early earn their price during this stretch.

Among the 53 GLP-1 telehealth providers we track, Eden Health (8.9/10) is our highest-rated provider for medical oversight: board-certified obesity-medicine physicians, quarterly lab panels, and the strongest verified customer record of any provider we track (4.5/5 across 3,777 Trustpilot reviews).

For comprehensive support across Zepbound's 24-week titration, this matters more than the price difference between programs.

See how all 53 providers score on clinical oversight in the full rankings, or take the 60-second match quiz to find providers that fit your support needs.

Wegovy side effects deep dive , for users comparing the two
Mounjaro side effects deep dive , same molecule (tirzepatide) at the diabetes indication
Ozempic side effects deep dive , semaglutide at diabetes doses (different molecule than Zepbound's tirzepatide)
Foundayo side effects deep dive , the new oral GLP-1 from Eli Lilly
Wegovy vs Zepbound: cost, side effects, and weight loss
Cross-drug GLP-1 side effects comparison , Wegovy vs Zepbound vs Foundayo vs Rybelsus rates side-by-side
FDA warning letter tracker , 50+ enforcement actions against GLP-1 providers since 2025
Provider safety checker , verify any GLP-1 telehealth program before enrolling

Sources

This page is for informational purposes only and is not medical advice. Always discuss medication decisions with a licensed prescriber. Side-effect rates are population averages from clinical trials and may not reflect your individual experience. If you are experiencing a medical emergency, call 911.